Genentech

Scientists at 23andMe and Genentech have identified 17 new genetic variants associated with Parkinson’s disease, almost doubling the total number of known risk variants for the condition, which gives scientists hints at potential new targets for drugs to treat the disease.

To mark Parkinson’s Awareness Month, we’re taking a moment to look at some of the accomplishments 23andMe has made in the study of the disease in a relatively short time....

This week 23andMe announced a collaboration with Pfizer Inc, allowing researchers with the drug maker to leverage 23andMe’s unique platform to conduct genome-wide associations studies, surveys and clinical trial recruitment....

Clinical trials are often conducted at major hospitals and medical centers.    As you can imagine, it can be expensive to use hospital resources and take a large amount of...